Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus FOAMICON.
ARAZLO vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid